Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Lowered by Leede Financial

Leede Financial lowered shares of Oncolytics Biotech (NASDAQ:ONCY) from a strong-buy rating to a moderate buy rating in a research note issued to investors on Wednesday morning,Zacks.com reports.

Separately, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Oncolytics Biotech in a report on Thursday.

Oncolytics Biotech Stock Down 3.0 %

Shares of ONCY stock opened at $0.98 on Wednesday. The firm has a market cap of $75.53 million, a price-to-earnings ratio of -3.63 and a beta of 1.69. Oncolytics Biotech has a 52-week low of $0.84 and a 52-week high of $1.75. The company’s 50 day moving average is $1.09 and its 200 day moving average is $1.06.

Hedge Funds Weigh In On Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC bought a new stake in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 0.07% of Oncolytics Biotech at the end of the most recent reporting period. 6.82% of the stock is currently owned by hedge funds and other institutional investors.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.